TIME has selected lecanemab as one of the best inventions of 2023 in the Medical Care category.
Lecanemab is based on BioArctic’s founder Professor Lars Lannfelt’s research. It is the first and only fully approved treatment in the US and Japan for patients with mild cognitive impairment or mild Alzheimer’s disease that targets the underlying disease and slows down cognitive decline.
Read more: FDA grants traditional approval for BioArctic’s LEQEMBI
“It feels fantastic that we are part of driving the paradigm shift currently happening globally in the treatment of Alzheimer’s disease,” says Gunilla Osswald, CEO, BioArctic.
Photo of Lars Lannfelt, founder: BioArctic
Advertisement
